Trial Research

 
News Articles for Trial Research top ^
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced top line results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the treatment of first-line HER2-positive locally recurrent or metastatic breast cancer (NEfERTT trial). The NEfERTT trial is a randomized, two-arm Phase II trial of neratinib plus the anticancer drug paclitaxel versus trastuzumab (Herceptin) plus paclitaxel as a first-line treatment for HER2- positive locally recurrent or metastatic breast cancer.
Sign-up for Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial) investment picks
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status Phase 2 Trial Informs Appropriate Apatorsen Dosing and Patient Population for Future Trials in Metastatic Bladder Cancer BOTHELL, Wash.
Sign-up for OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer investment picks
OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer Canada NewsWire AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
All Currently Enrolled Patients Can Continue Receiving Aldoxorubicin Therapy or Comparator Drugs; One Inclusion/Exclusion Criteria to be Amended for New Trial Patients to Add Additional Safety Measure Company Expects Trial Timelines to Remain Materially Unchanged LOS ANGELES , Nov.
Sign-up for CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials investment picks
- Trial results show novel S1P1 modulator produced strong, dose-dependent lymphocyte lowering - - No clinically significant safety findings relative to heart, liver or pulmonary function - SAN DIEGO , Jan.
Sign-up for Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases investment picks
Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch to SD-809 NDA Submission Planned by Mid-2015 Conference Call Scheduled for 4:30 PM ET / 1:30 PM PT Today LA JOLLA, Calif., Dec.
Sign-up for Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease investment picks
2014/10/29
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take drug again" when compared to I.V. pentazocine, a Schedule IV opioid analgesic Results suggest potential for I.V. CR845 to be first Schedule V or non-scheduled peripheral opioid for acute pain Conference Call/Webcast at 9:00 a.m. ET today SHELTON, Conn., Oct.
Sign-up for Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845 investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world’s leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Swedish Medical Products Agency (MPA) to initiate a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS-1) for the treatment of hepatic porphyrias, including acute intermittent porphyria (AIP). Per the filed CTA, the Phase 1 trial of ALN-AS1 will be performed first in AIP patients who are asymptomatic “high excreters” (ASHE) – patients with a mutation in the porphobilinogen deaminase (PBGD) gene and elevated urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) levels, but no recent symptoms of a porphyria attack – and then in AIP patients who experience recurrent porphyria attacks.
Sign-up for Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias investment picks
AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
Data From Part 1 of the Trial Will be Presented at the American Neurological Association Annual Meeting (ANA) ITI-007 is Safe and Well-Tolerated With a Dose-Related Pharmacokinetic Profile in Geriatric Subjects Consistent With Previous Studies NEW YORK, Oct.
Sign-up for Intra-Cellular Therapies Announces Topline Safety Results From Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced top line results for a Phase 2 clinical trial evaluating Sustained Release Dexamethasone (OTX-DP) for treatment of allergic conjunctivitis.
Sign-up for Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis investment picks
Trial expands the eligible patient population and overall NeuVax clinical trial portfolio Recent patent allowance provides intellectual property protection for NeuVax in combination with Herceptin in any HER2/neu expressing cancer PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients investment picks
State-of-the-art facility in Berlin-Schonefeld, Germany delivers end-to-end supply chain management and distribution services BOSTON , Nov.
Sign-up for PAREXEL Expands Clinical Trial Supply And Logistics Services Through Opening Of New European Coordination Hub and Distribution Center investment picks
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the activation of the first GENETIC-AF clinical trial site in Canada.
Sign-up for Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site investment picks
2014/12/30
-- On Schedule to Release Topline Data from Phase 1b Clinical Trial and to Start Phase 2 Clinical Trial of SYN-004 in 1Q 2015 --
Sign-up for Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection investment picks
ImmunoGen's stock (IMGN) plunged to a more than four-year low in very-active trade Friday afternoon, after Leerink Partners downgraded it to market perform from outperform, following disappointing trial results for Roche Holding's (RHHBY) . Leerink analyst Michael Schmidt also cut his stock price target to $7 from $15. Roche's drug Kadcyla utilizes ImmunoGen's antibody-drug conjugate technology.
Sign-up for ImmunoGen's stock plunges after Roche's disappointing trial results prompts downgrade investment picks
Biogen Idec (NASDAQ: BIIB) today announced top-line results from the Phase 2 acute optic neuritis (AON) RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.
Sign-up for Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis investment picks
Foundation Medicine, Inc. (NASDAQ: FMI) and EmergingMed today announced a partnership to offer personalized clinical trial navigation services to help health care providers and their patients who have received FoundationOne® or FoundationOne® Heme comprehensive genomic profiling.
Sign-up for Foundation Medicine Partners with EmergingMed to Offer Clinical Trial Navigation Services for Physicians and Patients investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Trial Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Trends Report  |  Next: Trial Results